Ezutromid Reduces Muscle Damage in DMD Patients, Interim Data of Phase 2 Trial Shows
Ezutromid significantly reduced muscle damage in patients with Duchenne muscular dystrophy (DMD)Â after 24 weeks of treatment in a Phase 2 trial, Summit Therapeutics recently announced. DMD is a severe type of muscular dystrophy caused by the absence of dystrophin, a protein…